Materiale Didattico Per Tutti gli AA
Pubblicazioni Scientifiche Usate per compilare le lezioni
- Sezione 1.0
- 1.5.1.0.0.0.0.1955.A notation for the study of certain stereochemical problems.pdf
- 1.5.1.0.0.0.0.Wedge and Dash Notation for 3D Chemical Structures.pdf
- 1.5.1.0.0.0.0.Wikipedia.Ball-and-stick_model.pdf
- 1.5.1.0.0.0.0.Wikipedia.Fischer_projection.pdf
- 1.5.1.0.0.0.0.Wikipedia.Newman_projection.pdf
- 1.5.1.0.0.0.0.Wikipedia.Simplified_molecular-input_line-entry_system.pdf
- 1.5.1.0.0.0.0.Wikipedia.Skeletal_formula.pdf
- 1.5.1.0.0.0.0.Wikipedia.wedge-and-dash.pdf
- 1.5.1.5.0.0.0.2006.Biomolecules in the computer. Jmol to the rescue.pdf
- 1.5.2.0.0.0.0.2006.The IUPAC International Chemical Identifier.pdf
- 1.5.2.0.0.0.0.2013.InChI - the worldwide chemical structure identifier standard.pdf
- 1.5.2.0.0.0.0.2021.InChI version 1.06. now more than 99.99_ reliable.pdf
- 1.5.2.0.0.0.0.InChI FAQ.pdf
- 1.5.2.1.0.0.0.2000.JChemPaint - Using the Collaborative Forces of the Internet to Develop a Free Editor for 2D Chemical Structures.pdf
- 1.5.2.2.0.0.0.2013.JSME. a free molecule editor in JavaScript.pdf
- 1.5.3.0.0.0.0.1988.SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules.pdf
- 1.5.3.0.0.0.0.1989.SMILES. 2. Algorithm for generation of unique SMILES notation.pdf
- 1.5.3.0.0.0.0.Daylight.Simplified_molecular-input_line-entry_system.pdf
- 1.5.4.0.0.0.0.2006.The IUPAC International Chemical Identifier.pdf
- 1.5.4.0.0.0.0.2013.InChI - the worldwide chemical structure identifier standard.pdf
- 1.5.4.0.0.0.0.Wikipedia.International_Chemical_Identifier.pdf
- 1.5.5.0.0.0.0.1992.Description of several chemical structure file formats.pdf
- 1.5.5.0.0.0.0.wikipedia.Chemical_table_file.pdf
- 1.5.6.0.0.0.0.Introduction to Protein Data Bank Format.pdf
- 1.5.6.0.0.0.0.PDB_Format_v33_A4.pdf
- 1.5.7.0.0.0.0.mol2_format.pdf
- 1.5.8.0.0.0.0.2011.Open Babel. An open chemical toolbox.pdf
- 1.5.8.0.0.0.0.Wikipedia.Open_Babel.pdf
- 1.6.1.0.0.0.0.2017.Protein Data Bank (PDB). The Single Global Macromolecular Structure Archive.pdf
- 1.6.2.0.0.0.0.2004.UCSF Chimera--a visualization system for exploratory research and analysis.pdf
- IntroductionJChemPaint.webm
- jchempaint-3.3-1210.jar
- JSME_2020-12-26.zip
- MarvinSketchChemAxonChemicalDrawingTool.mp4
- QuickChemsketchTutorial.mkv
- TutorialHowToBuildYourOwnMoleculeJSME.mkv
- Sezione 2.1
- Sezione 2.2
- Sezione 2.3
- 2.3.0.0.0.0.0.2004.The role of the medicinal chemist in drug discovery — then and now(1).pdf
- 2.3.0.0.0.0.0.2016.The Evolving Role of the Medicinal Chemist.pdf
- 2.3.0.0.0.0.0.2016.The Evolving Role of the Medicinal Chemist(1).pdf
- 2.3.0.0.0.0.0.2018.Improving the Efficiency of the Drug Development by Expanding the Scope of the Role of Medicinal Chemists in Drug Discovery.pdf
- 2.3.0.0.0.0.0.2018.Improving the Efficiency of the Drug Development by Expanding the Scope of the Role of Medicinal Chemists in Drug Discovery(1).pdf
- 2.3.0.0.0.0.0.2018.What Makes a Great Medicinal Chemist. A Personal Perspective.pdf
- 2.3.0.0.0.0.0.2018.What Makes a Great Medicinal Chemist. A Personal Perspective(1).pdf
- 2.3.0.0.0.0.0.Medicinal Chemistry - American Chemical Society.pdf
- 2.3.0.0.0.0.0.Medicinal Chemistry - American Chemical Society(1).pdf
- 2.3.0.0.0.0.0.The Medicinal Chemist Role in the World of AI - Proventa International.pdf
- 2.3.0.0.0.0.0.The Medicinal Chemist Role in the World of AI - Proventa International(1).pdf
- 2.3.0.0.0.0.0.The Practice of Medicinal Chemistry - Chapter 1.pdf
- 2.3.0.0.0.0.0.The Practice of Medicinal Chemistry - Chapter 1(1).pdf
- Sezione 2.4
- Sezione 2.4.1
- 2012.Natural products derived from plants as a source of drugs.pdf
- 2016.Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents.pdf
- 2019.Natural Products as a Foundation for Drug Discovery.pdf
- 2020.Plant Endophytes and Epiphytes. Burgeoning Sources of Known and “Unknown” Cytotoxic and Antibiotic Agents.pdf
- 2.4.0.0.0.0.0.1828.Ueber künstliche Bildung des Harnstoffs.pdf
- 2.4.0.0.0.0.0.2017.Drug development. Lessons from nature.pdf
- 2.4.0.0.0.0.0.Drug Development and Discovery _ CancerQuest.pdf
- 2.4.0.0.0.0.0.Guide-to-drug-discovery.pdf
- 2.4.0.0.0.0.0.Wikipedia.Organic_chemistry.pdf
- 2.4.0.0.0.0.0.Wikipedia.Wöhler_synthesis.pdf
- 2.4.1.0.0.0.0.2013.Natural products. A continuing source of novel drug leads.pdf
- 2.4.1.0.0.0.0.2015.Endophytic and epiphytic microbes as sources of bioactive agents.pdf
- 2.4.1.0.0.0.0.2020.Natural Products as Sources of New Drugs over the Nearly Four Decades from 01-1981 to 09-2019.pdf
- 2.4.1.0.0.0.0.2020.Plant Endophytes and Epiphytes.pdf
- 2.4.2.0.0.0.0.1959.Synthesis of Penicillin. 6-Aminopenicillanic Acid in Penicillin Fermentations.pdf
- 2.4.2.0.0.0.0.1994.Supercritical fluid extraction of taxol and baccatin III from needles of Taxus cuspidata.pdf
- 2.4.2.0.0.0.0.1998.A New Synthesis of Taxol from Baccatin III.pdf
- 2.4.2.0.0.0.0.1998.Process for obtaining 10-deacetylbaccatin III.US5736366.pdf
- 2.4.2.0.0.0.0.1998.The discovery of heroin.pdf
- 2.4.2.0.0.0.0.1999.A New Semisynthesis of Paclitaxel from Baccatin III.pdf
- 2.4.2.0.0.0.0.1999.Synthesis of paclitaxel from baccatin III.US6307071.pdf
- 2.4.2.0.0.0.0.2000.The discovery of aspirin. a reappraisal.pdf
- 2.4.2.0.0.0.0.2002.Monitoring of enzymatic hydrolysis of penicillin G by pyrolysis-negative ion mass spectrometry.pdf
- 2.4.2.0.0.0.0.2006.Single-pot conversion of cephalosporin C to 7-aminocephalosporanic acid using cell-bound and support-bound enzymes.pdf
- 2.4.2.0.0.0.0.2007.An Improved Manufacturing Process for the Antimalaria Drug Coartem. Part I.pdf
- 2.4.2.0.0.0.0.2007.The Echinocandins. Total and Semi-Synthetic Approaches in Antifungal Drug Discovery.pdf
- 2.4.2.0.0.0.0.2009.Single-pot conversion of cephalosporin C to 7-aminocephalosporanic acid in the absence of hydrogen peroxide.pdf
- 2.4.2.0.0.0.0.2014.Some Aspects in the Industrial Synthesis of Lactam Antibiotics.pdf
- 2.4.2.0.0.0.0.2017.The aspirin story – from willow to wonder drug.pdf
- 2.4.2.0.0.0.0.semisynthetic derivative (CHEBI_72588).pdf
- 2.4.2.0.0.0.0.Wikipedia.Semisynthesis.pdf
- 2.4.3.0.0.0.0.1936.Prontosil - TIME.pdf
- 2.4.3.0.0.0.0.2006.The First Miracle Drugs How the Sulfa Drugs Transformed Medicine.pdf
- 2.4.3.0.0.0.0.2015.Chemistry. Why synthesize.pdf
- 2.4.3.0.0.0.0.2015.Reinventing Chemistry.pdf
- 2.4.3.0.0.0.0.2020.Two-Phase Synthesis of Taxol.pdf
- 2.4.3.0.0.0.0.Wikipedia.Paclitaxel_total_synthesis.pdf
- 2.4.3.2.0.0.0.2015.Parallel Synthesis and Library Design.pdf
- 2.4.3.2.0.0.0.2018.Current Parallel Solid-Phase Synthesis of Drug-like Oxadiazole and Thiadiazole Derivatives for Combinatorial Chemistry.pdf
- 2.4.4.0.0.0.0.1963.Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide.pdf
- 2.4.4.0.0.0.0.1986.Solid phase synthesis.pdf
- 2.4.4.0.0.0.0.2009.Discovery of Innovative Small Molecule Therapeutics.pdf
- 2.4.4.0.0.0.0.2011.The rise, fall and reinvention of combinatorial chemistry.pdf
- 2.4.4.0.0.0.0.2013.COMBINATORIAL CHEMISTRY. A REVIEW.pdf
- 2.4.4.0.0.0.0.Wikipedia.Combinatorial_chemistry.pdf
- Sezione 3.0
- 3.0.0.0.0.0.0.2006.How many drug targets are there.pdf
- 3.1.0.0.0.0.1.Wikipedia.Biological_target.pdf
- 3.1.0.0.0.0.5.2013.Application of genomics, proteomics and metabolomics in drug discovery, development and clinic.pdf
- 3.1.1.0.0.0.1.2010.Principles of early drug discovery.pdf
- 3.1.2.0.0.0.1.2017.A comprehensive map of molecular drug targets.Original.pdf
- 3.1.2.0.0.0.3.2008.Drugs and their molecular targets. an updated overview.pdf
- 3.1.2.0.0.0.6.targets_and_families.csv
- 3.1.3.0.0.0.1.2020.An omics perspective on drug target discovery platform.pdf
- 3.1.3.0.0.0.4.2013.Use of genomics and proteomics in pharmaceutical drug discovery and development. A review.pdf
- 3.1.3.0.0.0.5.Wikipedia.Genomics.pdf
- 3.1.3.0.0.0.5.Wikipedia.Metabolomics.pdf
- 3.1.3.0.0.0.5.Wikipedia.Proteomics.pdf
- 3.1.3.0.0.0.6.2014.A draft map of the human proteome.pdf
- 3.1.3.0.0.0.7.2008.Proteomics and genomics. perspectives on drug and target discovery.pdf
- 3.1.3.0.0.0.7.2020.Target identification among known drugs by deep learning from heterogeneous networks.pdf
- 3.2.0.0.0.0.1.1950.The Origin of the Word Protein.pdf
- 3.2.0.0.0.0.1.Wikipedia.Protein_structure.pdf
- 3.2.0.0.0.0.1.Wikipedia.Protein.pdf
- 3.2.0.0.0.0.2.1951.Atomic Coordinates and Structure Factors for Two Helical Configurations of Polypeptide Chains.pdf
- 3.2.0.0.0.0.2.1951.The structure of proteins. Two hydrogen-bonded helical configurations of the polypeptide chain.pdf
- 3.2.0.0.0.0.3.2013.Book_MolecularBiology.pdf
- 3.2.0.0.0.0.4.2013.Patrick.Part_A.pdf
- 3.2.0.0.0.0.17.2018.Spider prey-wrapping silk is an α-helical coiled-coil-β-sheet hybrid nanofiber.pdf
- 3.2.0.0.0.0.18.2011.Nanoconfinement_of_spider_silk_fibrils_begets_supe.pdf
- 3.3.0.0.0.0.4.1997.RNA as a drug target.pdf
- 3.3.0.0.0.0.5.2019.Unveiling the druggable RNA targets and small molecule therapeutics.pdf
- 3.4.0.0.0.0.1.2007.Targeting the glycans of glycoproteins. a novel paradigm for antiviral therapy.pdf
- 3.4.0.0.0.0.5.2019.Glycans in drug discovery.pdf
- 3.4.0.0.0.0.6.2019.The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.pdf
- 3.4.0.0.0.0.7.2015.Glycans in the immune system and The Altered Glycan Theory of Autoimmunity. A critical review.pdf
- 3.5.0.0.0.0.1.2019.BigSMILES. A Structurally-Based Line Notation for Describing Macromolecules.pdf
- 3.6.0.0.0.0.1.2004.UCSF Chimera--a visualization system for exploratory research and analysis.pdf
- Sezione 4.0
- 4.2.1
- 4.2.1.0.0.0.1.Wikipedia.ADME.pdf
- 4.2.1.0.0.0.2b.Wikipedia.Iloprost.pdf
- 4.2.1.0.0.0.2c.Wikipedia.Articaine.pdf
- 4.2.1.0.0.0.3.2019.Book.BasicKnowledgeOfPharmacology.Pharmacokinetics.pdf
- 4.2.1.1.0.0.1.Wikipedia.Route_of_administration.pdf
- 4.2.1.2.0.0.1.1960.On the Mechanism of Absorption of Drugs from the Gastrointestinal Tract.pdf
- 4.2.1.2.0.0.1.1985.The absorption of β‐adrenoceptor antagonists in rat in‐situ small intestine. the effect of lipophilicity.pdf
- 4.2.1.2.0.0.1.2013.Pharmacokinetic - Patrick.pdf
- 4.2.1.2.0.0.7.2003.Tumor acidity, ion trapping and chemotherapeutics I.pdf
- 4.2.1.2.0.0.7.2003.Tumor acidity, ion trapping and chemotherapeutics II.pdf
- 4.2.1.2.0.0.8.Ion-Trapping, Microsomal Binding, and Unbound Drug Distribution in the Hepatic Retention of Basic Drugs.pdf
- 4.2.1.2.0.0.10.1987.Drug Absorption.pdf
- 4.2.1.2.0.0.10.1995.An Introduction to Drug Disposition. The Basic Principles of Absorption, Distribution, Metabolism, and Excretion.pdf
- 4.2.1.2.0.0.10.2002.A mechanistic approach to understanding the factors affecting drug absorption. a review of fundamentals.pdf
- 4.2.1.2.0.0.10.2018.Pharmacology, Part 2. Introduction to Pharmacokinetics.pdf
- 4.2.1.2.0.0.10.2021.Drug Absorption - StatPearls - NCBI Bookshelf.pdf
- 4.2.1.2.0.0.13.2017.Predicting Oral Drug Absorption. Mini Review on Physiologically-Based Pharmacokinetic Models.pdf
- 4.2.1.3.0.0.1.Wikipedia.Distribution_(pharmacology).pdf
- 4.2.1.3.0.0.8.Wikipedia.Plasma_protein_binding.pdf
- 4.2.1.3.0.0.9.1971.Effect of Binding to Plasma Proteins on the Distribution, Activity and Elimination of Drugs.pdf
- 4.2.1.3.0.0.10.2010.The effect of plasma protein binding on in vivo efficacy misconceptions in drug discovery.pdf
- 4.2.1.4.0.0.1.Wikipedia.Drug_metabolism.pdf
- 4.2.1.5.0.0.1.Wikipedia.Elimination_(pharmacology).pdf
- 4.2.1.5.0.0.2.Wikipedia.Nephron.pdf
- 4.2.1.5.0.0.6.2020.Drug Elimination - StatPearls - NCBI Bookshelf.pdf
- 4.2.1.5.0.0.7.2014.Drug Elimination.pdf
- 4.3
- 4.3.0.0.0.0.1.Drug Metabolism.pdf
- 4.3.0.0.0.0.1.Pharmacokinetics and related topics.pdf
- 4.3.1.0.0.0.1a.Wikipedia.Microsome.pdf
- 4.3.1.1.0.0.2.2001.Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity.pdf
- 4.3.1.1.0.0.2.McLean-Munro2018_ReferenceWorkEntry_CytochromeP450Cyp.pdf
- 4.3.1.1.0.0.2.Wikipedia.Cytochrome_P450.pdf
- 4.3.1.1.0.0.4.2013.Cytochrome P450 enzymes in drug metabolism. Regulation of gene expression, enzyme activities, and impact of genetic variation.pdf
- 4.3.1.1.0.0.9.2021.A history of the roles of cytochrome P450 enzymes in the toxicity of drugs.pdf
- 4.3.1.2.0.0.1.2000.The Catalytic Pathway of Cytochrome P450cam at Atomic Resolution.pdf
- 4.3.1.2.0.0.20.Metabolism of drugs and xenobiotics.pdf
- 4.3.1.2.0.0.23.Drug metabolism.pdf
- 4.3.1.2.0.0.28.2010.Human Liver Microsomal Cytochrome P450 3A Enzymes Involved in Thalidomide 5-Hydroxylation and Formation of a Glutathione Conjugate.pdf
- 4.3.1.2.0.0.33.2020.Inhibition and induction of CYP enzymes in humans. an update.pdf
- 4.3.2.0.0.0.1.2012.Phase_II_drug_metabolism.pdf
- 4.3.2.1.0.0.1.2001.Glucuronidation_J_Clin_Psychopharm.pdf
- 4.3.2.2.0.0.1.2001.Structure and Function of Sulfotransferases.pdf
- 4.3.2.2.0.0.1.2006.Human Sulfotransferases and Their Role in Chemical Metabolism.pdf
- 4.3.2.2.0.0.1.2012.Recent advances in sulfotransferase enzyme activity assays.pdf
- 4.3.2.3.0.0.1.1969.The Role of Glutathione and Glutathione S‐Transferases in Mercapturic Acid Biosynthesis.pdf
- 4.3.2.5.0.0.1.2013.Glycine conjugation.pdf
- 4.3.3.0.0.0.0.2015.Prodrug design _ perspectives, approaches and applications in medicinal chemistry.pdf
- 4.3.4.0.0.0.1.2003.Metabolic Stability for Drug Discovery and Development.pdf
- 4.3.5.0.0.0.1.1958.Chemical aspects of selective toxicity.pdf
- 4.3.5.0.0.0.1.2013.Prodrugs A challenge for the drug development.pdf
- 4.3.5.0.0.0.1.2018.The expanding role of prodrugs in contemporary drug design and development.pdf
- 4.3.5.0.0.0.1.2020.Prodrugs. My Initial Exploration and Where It Led.pdf
- 4.4
- 4.4.0.0.0.0.0.2007.Physicochemical Properties in Drug Profiling.pdf
- 4.4.0.0.0.0.0.2014.The Impact of Physicochemical and Molecular Properties in Drug Design. Navigation in the Drug-Like Chemical Space.pdf
- 4.4.1.0.0.0.12.1995.Partition Coefficient (n-octanol-water). Shake Flask Method.pdf
- 4.4.1.0.0.0.13.2001.Partition of solutes from the gas phase and from water to wet and dry di-n-butyl ether. a linear free energy relationship analysis.pdf
- 4.4.1.0.0.0.13.2007.Rapid method for estimating octanol-water partition coefficient (LOG Poct) from isocratic RP-HPLC and a hydrogen bond acidity term (A).pdf
- 4.4.1.0.0.0.16.2011.Flip-flop pharmacokinetics.pdf
- 4.4.2.0.0.0.1.2007.The pKa Distribution of Drugs. Application to Drug Discovery.SI.xls
- 4.4.4.1.0.0.0.2001.Experimental and computational approaches to estimate solubility and permeability.pdf
- 4.4.4.1.0.0.0.2001.Experimental and computational approaches to estimate solubility and permeability.right_column.pdf
- 4.4.4.1.0.0.0.2019.Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.SI.csv
- 4.4.4.2.0.0.0.2002.Molecular Properties That Influence the Oral Bioavailability of Drug Candidates.pdf
- 4.4.4.4.0.0.0.2003.A ‘Rule of Three’ for fragment-based lead discovery.pdf
- 4.4.4.5.0.0.1.2001.Simple Selection Criteria for Drug-like Chemical Matter.pdf
- 4.4.4.6.0.0.1.2000.Prediction of Drug Absorption Using Multivariate Statistics.pdf
- 4.4.5.0.0.0.1.2009.Drug-like property concepts in pharmaceutical design.pdf
- 4.5
- 4.5.1.0.0.0.1.Computer-Aided Prediction ofPharmacokinetic (ADMET)Properties.pdf
- 4.5.1.0.0.0.3.2016.Open source molecular modeling.pdf
- 4.5.1.0.0.0.4.2010.PaDEL‐descriptor. An open source software to calculate molecular descriptors and fingerprints.pdf
- 4.5.2.0.0.0.1.2017.SwissADME. a free web tool to evaluate pharmacokinetics.pdf
- 4.5.2.0.0.0.2.2018.ADMETlab. A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database.pdf
- 4.5.2.0.0.0.3.2015.pkCSM. predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures.pdf
- 2005.Strategy of Utilizing In Vitro and In Vivo ADME Tools for Lead Optimization and Drug Candidate Selection.pdf
- CDKDescUI-1.4.8.jar
- PaDEL-Descriptor.zip
- 4.6
- 4.6.1.2.1.0.1.Wikipedia.Lennard-Jones_potential.pdf
- 4.6.2.0.0.0.1.1973.Relationship between the Ki and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.pdf
- 4.6.2.2.0.0.1.2004.Ligand efficiency- a useful metric for lead selection.pdf
- 4.6.2.2.0.0.1.2005.Ligand efficiency indices as guideposts for drug discovery.pdf
- 4.6.2.2.0.0.1.Wikipedia.Lipophilic_efficiency.pdf
- 4.6.2.2.0.0.4.1999.The maximal affinity of ligands.pdf
- 4.6.3.0.0.0.2.1997.Introduction. Molecular Recognition.pdf
- 4.6.3.0.0.0.6.1894.Einfluss der Configuration auf die Wirkung der Enzyme.docx
- 4.6.3.0.0.0.10.1994.The Key-Lock Theory and the Induced Fit Theory.pdf
- 4.6.4.1.0.0.1.Wikipedia.Ligand_(biochemistry).pdf
- 4.6.4.1.0.0.3.Wikipedia.Binding_selectivity.pdf
- 4.6.4.2.0.0.1.2016.Enzyme Inhibitors and Activators.pdf
- 4.6.4.2.1.0.1.Wikipedia.Enzyme_Inhibitor.pdf
- 4.6.4.2.1.1.7.Wikipedia.Suicide_inhibition.pdf
- 4.6.4.2.1.1.7b.2012.Identification of Protein Targets of Reactive Metabolites of Tienilic Acid in Human Hepatocytes.pdf
- 4.6.4.2.1.1.9.2011.The resurgence of covalent drugs.pdf
- 4.6.4.2.1.1.9.2011.The resurgence of covalent drugs.SuppInfo.pdf
- 4.6.4.2.1.1.21.2015.Covalent inhibitors in drug discovery. From accidental discoveries to avoided liabilities and designed therapies.pdf
- 4.6.4.2.1.1.24.2019.Covalent Inhibition in Drug Discovery.pdf
- 4.6.4.2.1.1.29.2020.Covalent inhibitors. A rational approach to drug discovery.pdf
- 4.6.4.2.1.2.1.Wikipedia.Competitive_inhibition.pdf
- 4.6.4.2.1.2.2.Wikipedia.Uncompetitive_inhibitor.pdf
- 4.6.4.2.1.2.3.2003.8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase.pdf
- 4.6.4.2.1.2.3.Wikipedia.Non-competitive_inhibition.pdf
- 4.6.4.2.1.2.4.2016.The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.pdf
- 4.6.4.2.1.2.4.Wikipedia.Mixed_inhibition.pdf
- 4.6.4.2.2.0.1.2004.Enzyme Activation.pdf
- 4.6.4.2.2.0.1.2015.Design and Synthesis of Acetylenyl Benzamide Derivatives as Novel Glucokinase Activators for the Treatment of T2DM.pdf
- 4.6.4.2.2.0.1.Wikipedia.Enzyme_activator.pdf
- 4.6.4.3.0.0.1.2015.Silverman.Receptor.pdf
- 4.6.4.3.0.0.2.2004.Receptive Substances. John Newport Langley (1852–1925) and his Path to a Receptor Theory of Drug Action.pdf
- 4.6.4.3.0.0.4.2010.Paul Ehrlich (1854-1915). man with the magic bullet.pdf
- 4.6.4.3.0.0.4.Wikipedia.Paul_Ehrlich.pdf
- 4.6.4.3.0.0.5.Wikipedia.Magic_bullet_(medicine).pdf
- 4.6.4.3.0.0.6.Wikipedia.Receptor_(biochemistry).pdf
- 4.6.4.3.0.0.7.2018.The G protein-coupled receptors deorphanization landscape.pdf
- 4.6.4.3.0.0.7.Wikipedia.Orphan_receptor.pdf
- 4.6.4.3.1.0.1.Wikipedia.Agonist.pdf
- 4.6.4.3.2.0.1.Wikipedia.Receptor_antagonist.pdf
- 4.6.4.4.0.0.1.2001.Protacs. Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation.pdf
- 4.6.4.4.0.0.1.2019.PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future.pdf
- 4.6.4.4.0.0.1.Wikipedia.Proteolysis_targeting_chimera.pdf
- 4.1.0.0.0.0.1.Drug Activity Phases.pdf
- 4.2.0.0.0.0.0.Wikipedia.Pharmacokinetics.pdf
- Sezione 5.0
- 5.1
- 5.1.0.0.0.0.1.2010.How to improve RD productivity. the pharmaceutical industry_s grand challenge.pdf
- 5.1.0.0.0.0.1.2013.Patrick.Drug Discovery, Design and Development.pdf
- 5.1.0.0.0.0.1.2015.Silverman.Chapter_1.pdf
- 5.1.0.0.0.0.3.2020.An overview of drug discovery and development.pdf
- 5.1.0.0.0.0.4.2019.Fexinidazole. First Global Approval.pdf
- 5.1.0.0.0.0.5.2018.Assessing Pharmaceutical Research and Development Costs.pdf
- 5.1.0.0.0.0.6.Aptuit-Drug-Design-and-Discovery-eBook.pdf
- 5.1.0.0.0.0.8.Learn About Drug and Device Approvals - FDA.pdf
- 5.1.0.0.0.0.9.2017.Drug discovery and development. Role of basic biological research.pdf
- 5.1.0.0.0.0.17.Wikipedia.Drug_design.pdf
- 5.1.0.0.0.0.20.2019.The Stages of Drug Discovery and Development Proces.pdf
- 5.2
- 5.2.0.0.0.0.1.2006.Hit discovery and hit-to-lead approaches.pdf
- 5.2.0.0.0.0.2.2003.Hit and lead generation. beyond high-throughput screening.pdf
- 5.2.1.0.0.0.0.2015.Silverman.Chapter_2.1.pdf
- 5.2.1.0.0.0.1.2004.Facts, Figures and Trends in Lead Generation.pdf
- 5.2.1.0.0.0.1.2011.Principles of early drug discovery.pdf
- 5.2.1.0.0.0.1.2013.Patrick.Drug Discovery, Design and Development.pdf
- 5.2.1.0.0.0.22.2009.‘Me-Too’ Innovation in Pharmaceutical Markets.pdf
- 5.2.1.0.0.0.22.2020.Me-too pharmaceutical products. History, definitions, examples, and relevance to drug shortages and essential medicines lists.pdf
- 5.2.1.0.0.0.22.2020.Me‐too pharmaceutical products. History, definitions, examples, and relevance to drug shortages and essential medicines lists.pdf
- 5.2.2.1.0.0.1.2005.ZINC – A Free Database of Commercially Available Compounds for Virtual Screening.pdf
- 5.2.2.1.0.0.1.2012.ZINC. a free tool to discover chemistry for biology.pdf
- 5.2.2.1.0.0.1.2020.ZINC20—A Free Ultralarge-Scale Chemical Database for Ligand Discovery.pdf
- 5.2.2.2.0.0.1.2015.ChEMBL web services. streamlining access to drug discovery data and utilities.pdf
- 5.2.2.2.0.0.1.2019.ChEMBL. towards direct deposition of bioassay data.pdf
- 5.2.2.2.0.0.1.Wikipedia.ChEMBL.pdf
- 5.2.2.3.0.0.1.2008.PubChem. Integrated Platform of Small Molecules and Biological Activitiess.pdf
- 5.2.2.3.0.0.1.2020.PubChem in 2021. new data content and improved web interfaces.pdf
- 5.2.2.3.0.0.1.Wikipedia.PubChem.pdf
- 5.2.2.4.0.0.1.2007.BindingDB a web-accessible database of experimentally determined protein–ligand binding affinities.pdf
- 5.2.2.4.0.0.1.2015.BindingDB in 2015. A public database for medicinal chemistry, computational chemistry and systems pharmacology.pdf
- 5.2.2.4.0.0.1.Wikipedia.BindingDB.pdf
- 5.2.2.5.0.0.1.2006.DrugBank. a comprehensive resource for in silico drug discovery and exploration.pdf
- 5.2.2.5.0.0.1.2008.DrugBank. a knowledgebase for drugs, drug actions and drug targets.pdf
- 5.2.2.5.0.0.1.2018.DrugBank 5.0. a major update to the DrugBank database for 2018.pdf
- 5.2.2.6.0.0.1.2018.The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.pdf
- 5.2.3.0.0.0.1.Wikipedia.Hit_to_lead.pdf
- 5.2.5.0.0.0.1.2001.Is There a Difference between Leads and Drugs. A Historical Perspective.pdf
- 5.2.5.0.0.0.1.2004.Lead- and drug-like compounds. the rule-of-five revolution.pdf
- 5.2.5.0.0.0.1.2007.The influence of drug-like concepts on decision-making in medicinal chemistry.pdf
- 5.2.5.0.0.0.1.2009.Efficient Drug Lead Discovery and Optimization.pdf
- 5.3
- 5.4
- 5.4.1.1.0.0.3.1865.On the Connection between Chemical Constitution and Physiological Action.pdf
- 5.4.1.1.0.0.8.2005.Structure-Activity Relationships for the Design of Small-Molecule Inhibitors.pdf
- 5.4.1.1.0.0.9.2013.On Exploring Structure Activity Relationships.pdf
- 5.4.1.1.0.0.11.2018.The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist’s Education.pdf
- 5.4.1.1.0.0.12.2000.The Practice of Structure Activity Relationships (SAR) in Toxicology.pdf
- 5.4.1.1.0.0.19.2012.SAR Matrices. Automated Extraction of Information-Rich SAR Tables from Large Compound Data Sets.pdf
- 5.4.1.1.0.0.19.2015.Monitoring the Progression of Structure–Activity Relationship Information during Lead Optimization.pdf
- 5.4.1.1.0.0.19.2019.Integrating the Structure–Activity Relationship Matrix Method with Molecular Grid Maps.pdf
- 5.4.1.1.0.0.22.2019.Understanding SAR for Trypanosomal Cysteine Protease Inhibitors by Simulations and Free Energy Calculations.pdf
- 5.4.1.2.1.0.1.2004.Selective Optimization of Side Activities. Another Way for Drug Discovery.pdf
- 5.4.1.2.1.0.1.2006.Selective optimization of side activities the SOSA approach.pdf
- 5.4.1.2.1.0.10.2021.Selective Optimization of Side Activities (SOSA) as an Efficient Approach for Generation of New Leads from Old Drugs.pdf
- 5.4.1.2.2.0.1.2002.Structure-based screening of low-affinity compounds.pdf
- 5.4.1.2.2.0.14.2003.A ‘Rule of Three’ for fragment-based lead discovery.pdf
- 5.4.1.2.2.0.14.2013.The _rule of three_ for fragment-based drug discovery. where are we now.pdf
- 5.4.1.2.2.0.16.2004.Fragment-based lead discovery.pdf
- 5.4.1.2.2.0.27.2019.A bright future for fragment-based drug discovery. what does it hold.pdf
- 5.4.1.2.2.0.29.2020.Application of Fragment-Based Drug Discovery to Versatile Targets.pdf
- 5.4.1.2.3.0.1.1946.Biological Activity of Compounds in Homologous Series.pdf
- 5.4.1.2.3.0.5.1946.The Pharmacology of Homologous Series.pdf
- 5.4.1.2.3.0.7.Wikipedia.Homologation_reaction.pdf
- 5.4.1.2.3.0.10.2004.Kowalski Ester Homologation. Application to the Synthesis of β-Amino Esters.pdf
- 5.4.1.2.4.0.1.1926.Zu den O‐Alkylderivaten des Benzoyl‐acetons und den aus ihnen entstehenden Isoxazolen.pdf
- 5.4.1.2.4.0.1.1934.The Principle of Vinylogy.pdf
- 5.4.1.2.4.0.6.2003.Molecular Variations in Homologous Series. Vinylogues and Benzologues.pdf
- 5.4.1.2.5.0.1.Wikipedia.Stereochemistry.pdf
- 5.4.1.2.5.0.3.Wikipedia.Cahn–Ingold–Prelog_priority_rules.pdf
- 5.4.1.2.5.0.4.2018.Algorithmic Analysis of Cahn–Ingold–Prelog Rules of Stereochemistry.pdf
- 5.4.1.2.5.0.7.2000.Mechanism of Action in Thalidomide Teratogenesis.pdf
- 5.4.1.2.5.0.9.2011.Effect of Stereochemistry in Medicinal Chemistry and Drug Discovery.pdf
- 5.4.1.2.5.0.10.2011.The Significance of Chirality in Drug Design and Development.pdf
- 5.4.1.2.5.0.21.1933.Studies on the relationship between chemical constitution and physiological action.pdf
- 5.4.1.2.5.0.23.2006.Chiral Drugs. An Overview.pdf
- 5.4.1.2.5.0.27.Wikipedia.Eudysmic_ratio.pdf
- 5.4.1.2.5.0.28.1978.Stereoselectivity and affinity in molecular pharmacology.original.pdf
- 5.4.1.2.5.0.28.1978.Stereoselectivity and affinity in molecular pharmacology.pdf
- 5.4.1.2.5.0.29.2008.Analysis of Efficacy of Chiral Adrenergic Agonist.pdf
- 5.4.1.2.5.0.30.Structure–function of a1-adrenergic receptor.pdf
- 5.4.1.2.5.0.33.2014.STEREOCHEMISTRY AND ITS ROLE IN DRUG DESIGN.pdf
- 5.4.1.2.6.0.1.2019.Structural simplification. an efficient strategy in lead optimization.pdf
- 5.4.1.2.7.0.1.2014.Conformational restriction. An effective tactic in _follow-on_-based drug discovery.pdf
- 5.4.1.2.7.0.9.2013.An Introduction to Medicinal Chemistry.Rigidification of the structure.pdf
- 5.4.1.2.8.0.1.2008.Homo and Heterodimer Ligands. the Twin Drug Approach.pdf
- 5.4.1.2.8.0.18.2005.Designed Multiple Ligands. An Emerging Drug Discovery Paradigm.pdf
- 5.4.1.2.8.0.32.2006.The Physicochemical Challenges of Designing Multiple Ligands.pdf
- 5.4.1.2.8.0.33.2008.Dimeric Approaches to Anti-Cancer Chemotherapeutics.pdf
- 5.4.1.2.8.0.35.2019.Double the Chemistry, Double the Fun.pdf
- 5.4.1.2.9.0.1.2012.The Use of Bioisosterism in Drug Design and MolecularModification.pdf
- 5.4.1.2.9.0.4.1919.Isomorphism, isosterism and covalence.pdf
- 5.4.1.2.9.0.8.1925.Über Bau und Grösse der Nichtmetallhydride.pdf
- 5.4.1.2.9.0.10.1932.Uber Pseudoatome.pdf
- 5.4.1.2.9.0.10.1935.Zusammenhänge zwischen Konstitution und Wirkung bei Pyrazolonderivaten.pdf
- 5.4.1.2.9.0.12.1950.Influence of Isosteric Replacements upon Biological Activity.pdf
- 5.4.1.2.9.0.15.1996.Bioisosterism. A Rational Approach in Drug Design.pdf
- 5.4.1.2.9.0.26.2020.Craig plot 2.0. an interactive navigation in the substituent bioisosteric space.pdf
- 5.4.1.2.10.0.1.2004.Scaffold hopping.pdf
- 5.4.1.2.10.0.5.2006.On scaffolds and hopping in medicinal chemistry.pdf
- 5.4.1.2.10.0.6.2017.Recent Advances in Scaffold Hopping.pdf
- 5.4.2.0.0.0.0.2018.TOOLS FOR LIGAND BASED DRUG DISCOVERY.pdf
- 5.4.2.0.0.0.0.Wikipedia.Pharmacophore.pdf
- 5.4.2.2.1.0.0.2011.Pharmacophores for medicinal chemists.pdf
- 5.4.2.2.1.0.1.2013.Glossary of Terms Used in Medicinal Chemistry.pdf
- 5.4.2.2.1.0.1.2014.Glossary of Terms Used in Medicinal Chemistry_II.pdf
- 5.4.2.2.1.0.5.2003.Pharmacophore Discovery – Lessons Learned.pdf
- 5.4.2.2.1.0.11.2017.Privileged Structures Revisited.pdf
- 5.4.2.2.1.0.27.2004.From magic bullets to designed multiple ligands.pdf
- 5.4.2.2.1.0.37.2010.Pharmacophore modeling and applications in drug discovery. challenges and recent advances.Pharmacophore.1.pdf
- 5.4.2.2.2.0.0.2003.General Introduction to QSAR.pdf
- 5.4.2.2.2.1.4.1952.Polar and Steric Substituent Constants for Aliphatic and o-Benzoate Groups from Rates of Esterification and Hydrolysis of Esters.pdf
- 5.4.2.2.2.1.7.1951.Further Evidence For a Chemical Reaction Between Plant Growth-Regulators and a Plant Substrate.pdf
- 5.4.2.2.2.2.1.1951.Further Evidence For a Chemical Reaction Between Plant Growth-Regulators and a Plant Substrate.pdf
- 5.4.2.2.2.2.1.1955.Chemical Constitution as Related to Grwoth Regulator Action.pdf
- 5.4.2.2.2.2.1.1963.The Correlation of Biological Activity of Plant Growth Regulators and Chloromycetines with Hammett Constants and logP.pdf
- 5.4.2.2.2.2.2.1964.p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure.pdf
- 5.4.2.2.2.2.3.1967.The Use of Substituent Constants in Drug Design.pdf
- 5.4.2.2.2.2.4.1968.Physicochemical Parameters in Drug Design.pdf
- 5.4.2.2.2.2.5.1967.Structure-Activity Relationship in the Auxin Activity of Mono-Substituted Phenylacetic Acids.pdf
- 5.4.2.2.2.2.6.1969.A Quantitative approach to biochemical structure-activity relationships.pdf
- 5.4.2.2.2.3.1.1964.A Mathematical Contribution to Structure-Activity Studies.pdf
- 5.4.2.2.2.4.1.1971.Structure-activity study of phenethylamines as substrates of biosynthetic enzymes of sympathetic transmitters.pdf
- 5.4.2.2.2.4.2.1988.Free Wilson Analysis. Theory, Applications and its Relationship to Hansch Analysis.pdf
- 5.4.2.2.2.4.3.1998.A Combined Hansch-Free‐Wilson Approach.pdf
- 5.4.2.2.2.6.1.2012.Hansch analysis 50 years on.pdf
- 5.4.2.2.2.6.6.2014.QSAR Modeling. Where Have You Been. Where Are You Going To.pdf
- 5.4.2.2.2.6.8.2013.Beyond the Scope of Free-Wilson Analysis. Building Interpretable QSAR Models with Machine Learning Algorithms.pdf
- 5.4.2.2.2.6.9.2019.Conformational Effects on Physical-Organic Descriptors. The Case of Sterimol Steric Parameters.pdf
- 5.4.2.2.2.6.10.1987.Principal component analysis.pdf
- 5.4.2.2.2.6.10.2020.QSPR-QSAR. State-of-Art, Weirdness, the Future.pdf
- 5.4.2.2.2.6.12.1987.Multi‐way principal components‐and PLS‐analysis.pdf
- 5.4.2.2.2.6.13.Partial Least Squares (PLS). Its strengths and limitations.pdf
- 5.4.2.2.2.6.14.2006.On outliers and activity cliffs--why QSAR often disappoints.pdf
- 5.4.2.2.2.6.15.2007.OECD Guidance Document on the Validation of (Q)SAR Models.pdf
- 5.4.2.2.2.6.16.2009.Basic validation procedures for regression models in QSAR and QSPR studies. theory and application.pdf
- 5.4.2.2.2.6.16.2009.Basic validation procedures for regression models in QSAR and QSPR studies. theory and application.SI.pdf
- 5.4.2.2.2.6.17.2010.Best Practices for QSAR Model Development, Validation, and Exploitation.pdf
- 5.4.2.2.2.7.12.1970.The assumptions of the linear regression model.pdf
- 5.4.2.2.2.7.14.1971.Interdependence between physical parameters and selection of substituent groups for correlation studies.pdf
- 5.4.2.2.2.7.15.1979.Chance factors in studies of quantitative structure-activity relationships.pdf
- 5.4.2.2.2.7.22.2018.Mordred. a molecular descriptor calculator.pdf
- 5.4.2.2.2.7.29.1984.The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses.pdf
- 5.4.2.2.2.7.31.1993.Partial Least Squares (PLS). Its strengths and limitations.pdf
- 5.4.2.2.2.7.31.1993.The Probability of Chance Correlation Using Partial Least Squares (PLS).pdf
- 5.4.2.2.2.7.x.2005.Assessing QSAR Limitations – A Regulatory Perspective.pdf
- 5.4.2.2.2.8.6.1988.Comparative Molecular Field Analysis (CoMFA).CoMFA.1.pdf
- 5.4.2.2.2.8.17.2001.Flexible Alignment of Small Molecules.pdf
- 5.4.2.2.2.8.18.2009.ShaEP. Molecular Overlay Based on Shape and Electrostatic Potential.pdf
- 5.4.2.2.2.8.19.2010.3D-QSAR in drug design--a review.pdf
- 5.4.2.2.2.8.20.2020.Teaching and Learning Computational Drug Design.pdf
- 5.4.2.3.0.0.2.2000.Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with ligand-based methods.pdf
- 5.4.2.3.0.0.3.The development of a simple empirical scoring function.pdf
- 5.4.2.3.0.0.4.Docking and scoring in virtual screening for drug discovery. methods and applications.pdf
- 5.4.2.3.0.0.5.Protein-Ligand Docking in the New Millennium – A Retrospective of 10 Years in the Field.pdf
- 5.4.2.3.0.0.6.Prediction of Drug Binding Affinities by Comparative Binding Energy Analysis.COMBINE.1.1995.pdf
- 5.4.2.3.0.0.7.Comparative Binding Energy Analysis Considering Multiple Receptors. A Step toward 3D-QSAR Models for Multiple Targets.pdf
- 5.4.2.3.0.0.8.2005.Proteochemometrics. A Tool for Modeling the Molecular Interaction Space.pdf
- 5.4.2.3.0.0.9.2019.Proteochemometrics – recent developments in bioactivity and selectivity modeling.pdf
- 5.4.2.3.0.0.10.2016.Role of Molecular Dynamics and Related Methods in Drug Discovery.pdf
- 5.4.2.3.0.0.11.2014.Structure-based three-dimensional pharmacophores as an alternative to traditional methodologies.pdf
- 5.4.2.3.0.0.12.2018.Homology modeling in drug discover.pdf
- Sezione 6.0
- 6.1
- 6.2
- 6.3
- 6.3.0
- 6.3.1
- 6.3.1.1
- 6.3.1.1.0.0.5.2010.A brief history of the antibiotic era. lessons learned and challenges for the future.pdf
- 6.3.1.1.0.0.6.2016.Antibiotics. from prehistory to the present day.pdf
- 6.3.1.1.0.0.8.1980.Tetracycline-labeled human bone from ancient Sudanese Nubia (A.D. 350).pdf
- 6.3.1.1.0.0.14.2019.Antibiotic Discovery. Where Have We Come from, Where Do We Go.pdf
- 6.3.1.1.0.0.15.2019.Antibiotics. past, present and future.pdf
- 6.3.1.1.0.0.16.2015.A new antibiotic kills pathogens without detectable resistance.pdf
- 6.3.1.1.0.0.16.2017.History of antimicrobial drug discovery. Major classes and health impact.pdf
- 6.3.1.1.0.0.17.2019.Antibacterial Aromatic Polyketides Incorporating the Unusual Amino Acid Enduracididine.pdf
- 6.3.1.1.0.0.20.2012.The Antibacterial Drug Discovery.pdf
- 6.3.1.2
- 6.3.1.3
- 6.3.1.4
- 6.3.2
- 6.3.3
- Video
- 6.3.3.0.0.0.1.1998.Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.pdf
- 6.3.3.0.0.0.3.2019.The Mycobacterium tuberculosis capsule. a cell structure with key implications in pathogenesis.pdf
- 6.3.3.0.0.0.8.2018.Drug targets exploited in Mycobacterium tuberculosis.pdf
- 6.3.3.0.0.0.14.2003.The current anti-TB drug research and development pipeline.pdf
- 6.3.3.0.0.0.17.2011.The Medicinal Chemistry of Tuberculosis Chemotherapy.pdf
- 6.3.3.0.0.0.33.2019.An overview of new antitubercular drugs, drug candidates, and their targets.pdf
- 6.3.3.0.0.0.48.2021.Riminophenazine Derivatives as Potential Antituberculosis Agents. Synthesis, Biological, and Electrochemical Evaluations.pdf
- 6.3.3.0.0.0.60.2014.Preparation method for bedaquiline.pdf
- 6.3.3.0.0.0.61.2015.An elegant synthesis of indoloquinoline alkaloid cryptotackieine via Vilsmeier-Haack approach.pdf
- 6.3.3.0.0.0.70.2006.OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis.pdf
- 6.3.3.0.0.0.81.2006.Synthesis and Antituberculosis Activity of a Novel Series of Optically Active oxazoles.pdf
- 6.3.3.0.0.0.83.2011.Synthetic intermediate of oxazole compound and method for producing the same.pdf
- 6.3.3.0.0.0.85.1980.The first practical method for asymmetric epoxidation.pdf
- 6.3.3.0.0.0.85.1984.Crystal structures of two titanium tartrate asymmetric epoxidation catalysts.pdf
- 6.3.3.0.0.0.87.1993.1,1′-(azodicarbonyl)dipiperidine-tributylphosphine, a new reagent system for mitsunobu reaction.pdf
- 2011.Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles.pdf
- 2015.Delamanid. A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis.pdf
- 2015.Synthesis of new generation triazolyl and isoxazolyl containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB.pdf
- 2017.Antitubercular Nitroimidazoles Revisited. Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.pdf
- 6.3.4
- Video
- 6.3.4.0.0.0.7.1980.Ivermectin, a new broad-spectrum antiparasitic agent.pdf
- 6.3.4.0.0.0.8b.2021.Ivermectin. An Anthelmintic, an Insecticide, and Much More.pdf
- 6.3.4.0.0.0.9.2011.Antiparasitic Therapy.pdf
- 6.3.4.0.0.0.9.2020.Antiparasitic Drugs - StatPearls - NCBI Bookshelf.pdf
- 6.3.4.1.2.0.46.2010.Next-Generation Antimalarial Drugs.pdf
- 6.3.4.1.3.0.29.2018.Review on structural-activity relationship (SAR) using antimalarial drug design as a case study.pdf
- 6.3.4.1.4.0.3.2008.Confirmation of the Rabe–Kindler Conversion of d-Quinotoxine Into Quinine.pdf
- 6.3.4.1.4.0.4.2001.The First Stereoselective Total Synthesis of Quinine.pdf
- 6.3.4.1.4.0.4.2018.C−H Activation Enables a Concise Total Synthesis of Quinine and Analogues.pdf
- 6.3.4.1.4.0.5.1949.CHLOROQUINE MANUFACTURE.pdf
- 6.3.4.1.4.0.5.2001.One pot synthesis of a mefloquine intermediate.US6500955.pdf
- 6.3.4.1.4.0.5.2011.Asymmetric Total Synthesis of the Antimalarial Drug (+)-Mefloquine Hydrochloride.pdf
- 6.3.4.1.4.0.5.QUINOLINE COMPOUND AND PROCESS OF MAKEING THE SAME.US2233970.pdf
- 6.3.4.1.4.0.13.1952.Process for the preparation and manufacture of primaquine.US2604474.pdf
- 6.3.4.1.4.0.13.2005.Primaquine Diphosphate. Comprehensive Profile.pdf
- 6.3.4.1.4.0.14.1955.Synthesis of Primaquine and Certain of its Analogs.pdf
- 6.3.4.1.4.0.16.Skraup_reaction.pdf
- 6.3.4.1.4.0.17.1880.Eine Synthese des quinolins.pdf
- 6.3.4.1.4.0.18.1887.Ueber eine Darstellungsweise primärer Amine aus den entsprechenden Halogenverbindungen.pdf
- 6.3.5
- Video
- 6.3.5.3.3.0.1.2012.Transition states of native and drug-resistant HIV-1 protease are the same.pdf
- 6.3.5.3.7.1.18.2006.Title Iridium-catalyzed borylation of arenes and heteroarenes via C-H activation.pdf
- 6.3.5.3.7.2.7.2006.Meldrum_s Acid in Multicomponent Reactions.pdf
- 6.3.5.3.7.2.8.2009.Dimethylformamide dimethyl acetal as a building block in heterocyclic synthesis.pdf
- 6.3.5.3.7.2.13.1981.N-methoxy-n-methylamides as effective acylating agents.pdf
- 6.3.5.3.7.2.14.1999.100 Years of Baeyer–Villiger Oxidations.pdf
- 6.3.5.3.7.3.3.2004.Novel arylsulfonamides possessing sub-picomolar HIV protease activities.pdf
- 6.3.5.3.7.3.7.2004.Stereoselective Photochemical 1,3-Dioxolane.pdf
- 6.3.5.4.3.0.5.2002.The Uronium-Guanidinium Peptide Coupling Reagents. Finally the True Uronium Salts.pdf
- 6.3.5.4.3.0.6b.1899.Barbier reaction 1.jpg
- 6.3.5.4.3.0.6b.1899.Barbier reaction 2.jpg
- 6.3.5.4.3.0.6b.1899.Barbier reaction 5.jpg
- 2016.HIV reservoirs. what, where and how to target them.pdf
- 2019.Long-Acting HIV Drugs for Treatment and Prevention.pdf
- 2020.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults.pdf
- Video
- 6.3.1.6.0.0.1.From DNA to protein - 3D.mp4
- 6.3.1.6.0.0.3.Bacterial Protein synthesis - Initiation, Elongation and Termination.mkv
- 6.3.1.6.0.0.5.ribosome Full 3D strecture.mp4
- 6.3.1.6.1.0.2.Pharmacology AnimationProtein Synthesis Inhibitors antibiotics animation video.mp4
- 6.3.1.6.2.0.11.Aminoglycosides_ Mechanism of action.mp4
- 6.3.1.6.2.0.11.Gentamicin_ Mechanism of Action.mp4
- 6.3.1.6.2.0.12.Mechanisms of Aminoglycoside Antibiotic Resistance.mp4
- 6.3.1.6.3.0.2.Tetracycline Mechanism of Action.mp4
- 6.3.1.6.3.0.2.Tetracycline_ Mechanism of action.mp4
- 6.3.1.6.4.0.2.Chloramphenicol_ Mechanism of action.mp4
- 6.3.1.6.4.0.2.Mechanism of Action of the Antibiotic CHLORAMPHENICOL on the 70S Ribosome.mp4
- 6.3.1.6.5.0.3.Macrolides _ Mechanism of action.mp4
- 6.3.1.6.5.0.3.Macrolides - Mechanisms of Action and Resistance.webm
- 6.3.1.6.5.0.8. Macrolides Detailed Pharmacology Animated - Mechanism of action, Kinetics, Resistance.mp4
- 6.3.1.6.6.0.3.Linezolid(Zyvox) - Mechanism of action.mkv
- 6.3.1.6.6.0.6.Oxazolidinones Animation_360p.mp4
- 6.3.2.0.0.0.2.Aspergillosis_360p.mp4
- 6.3.2.0.0.0.2.Candidemia_Invasive Candidiasis Treatment Algorithm.mp4
- 6.3.2.0.0.0.2.Candiduria Risk Factors Symptoms and Treatment_360p.mp4
- 6.3.2.0.0.0.2.Defenses Against Candida Species_360p.mp4
- 6.3.2.0.0.0.2.Elsevier IndiaMechanism of action of antifungal drugs.mp4
- 6.3.2.0.0.0.2.Extrapulmonary Aspergillosis_360p.mp4
- 6.3.2.0.0.0.2.Fungal Infection in Bone Marrow Transplant Recipient_360p.mp4
- 6.3.2.0.0.0.2.Overview of the Fungal Cell Structure.mp4
- 6.3.2.0.0.0.2.Sources of Candida Organisms_360p.mp4
- 6.3.2.0.0.0.16b.Mechanisms in MedicineThe Role of Azoles.mp4
- 6.3.2.0.0.0.18b.Mechanisms in MedicineThe Role of Amphotericin.mp4
- 6.3.2.0.0.0.18b.Pharmacology AnimationAmphotericin B animation.mp4
- 6.3.2.0.0.0.20b.Mechanisms in MedicineThe Role of Echinocandins.mp4
- 6.3.2.0.0.0.20b.Pharmacology AnimationEchinocandins animation.mp4
- 6.3.2.0.0.0.22.Pharmacology AnimationAzoles And Terbinafine antifungal animation.mp4
- 6.3.2.1.0.0.33.Speed PharmacologyPharmacology – ANTIFUNGAL DRUGS (MADE EASY).mkv
- 6.3.2.1.0.0.56.Biofilm_.mp4
- Cell Wall Synthesis.mp4
- Efflux.mp4
- Fluoroquinolones_ Mechanisms of Action and Resistance.mp4
- Horizontal Gene Transfer and Antibiotic Resistance.mp4
- La vita e la straordinaria scoperta di Vincenzo Tiberio-EiM1T4hyEpE.mkv
- Macrolides_ Mechanisms of Action and Resistance.mp4
- Mechanism of action of Penicillin Cephalosporin Vancomycin Cycloserine Bacitracin beta lactam_360p.mp4
- Metronidazole _ Bacterial Targets, Mechanism of Action, Adverse Effects.mp4
- Mutations - selection_ the bacteria resist.mp4
- Potassium Capture by Valinomycin.mp4
- ß-Lactams_ Mechanisms of Action and Resistance.mp4
- Vancomycin _ Bacterial Targets, Mechanism of Action, Adverse Effects.mp4
- Vincenzo Tiberio e la vera scoperta della penicillina a Napoli.mkv
- 6.4
- 6.4.0.0.0.0.1.2019.Bookshelf_NBK548487.pdf
- 6.4.1.0.0.0.2.2020.Antiemetics. types, actions and uses.pdf
- 6.4.2.0.0.0.2.2005.Efficacy and safety of bisacodyl in the acute treatment of constipation.pdf
- 6.4.2.0.0.0.4.2018.Cytotoxicity of Structurally Diverse Anthranoids.pdf
- 6.4.2.0.0.0.5.Cascara Sagrada_ Uses, Botanical Source, Characters, and Chemical Constituents.pdf
- 6.4.2.0.0.0.10.1955.USE OF DIOCTYL SODIUM SULFOSUCCINATE (AEROSOL O. T.) FOR SEVERE CONSTIPATION.pdf
- 6.4.2.0.0.0.12.2017.Plecanatide. First Global Approval.pdf
- 6.4.2.0.0.0.13.1999.Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.pdf
- 6.4.2.0.0.0.13.Wikipedia.Plecanatide.pdf
- 6.4.2.0.0.0.15.2014.Advances in the management of constipation-predominant irritable bowel syndrome. the role of linaclotide.pdf
- 6.4.3.0.0.0.0.2015.Pharmacologic Agents for Chronic Diarrhea.pdf
- 6.4.3.0.0.0.2.2003.Treatment of diarrheal disease.pdf
- 6.4.3.2.0.0.7.2003.Management of acute cancer treatment-induced diarrhea.pdf
- 6.4.3.3.0.0.4.1986.In vivo ‘enkephalinase’ inhibition by acetorphan in human plasma and CSF.pdf
- 6.4.3.3.0.0.6.1973.Synthetic antidiarrheal agents. 2,2-Diphenyl-4-(4_-aryl-4_-hydroxypiperidino)butyramides.pdf
- 6.4.3.3.0.0.8.2019.The role of antispasmodics in managing irritable bowel syndrom.pdf
- 6.4.3.4.0.0.2.2003.Management of infectious diarrhoea.pdf
- 6.4.3.4.0.0.4.2017.Antibiotic Therapy for Acute Watery Diarrhea and Dysentery.pdf
- 6.4.3.4.0.0.5.2005.Rifaximin. a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.pdf
- 6.4.3.4.0.0.6.2007.Therapy for and Prevention of Traveler_s Diarrhea.pdf
- 6.4.3.6.0.0.1.2014.Systematic review. the management of chronic diarrhoea due to bile acid malabsorption.pdf
- 6.4.4.0.0.0.2.2019.Peptic Ulcer Disease. A Brief Review of Conventional Therapy and Herbal Treatment Options.pdf
- 6.4.4.0.0.0.7.1999.Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs.pdf
- 6.4.4.1.0.0.3.1964.Rationale for the use of anticholinergic agents in the management of duodenal ulcer.pdf
- 6.4.4.1.0.0.5.1988.Role of the Cholinergic Nervous System in Acid Secretion.pdf
- 6.4.4.1.0.0.7.1985.Pirenzepine. a selective anticholinergic for peptic ulcer,pdf.pdf
- 6.4.4.2.0.0.4.1994.The development of cimetidine.pdf
- 6.4.4.2.0.0.8.1989.US4855439.Process for the preparation of cimetidine.pdf
- 6.4.4.2.0.0.11.2001.HISTAMINE H2-ANTAGONISTS.pdf
- 6.4.4.3.0.0.1.1987.Antiulcer activity of clonidine. lack of effect on gastric prostaglandins.pdf
- 6.4.4.3.0.0.2.2012.The Role of Alpha-2 Adrenergic Receptors in Anti-ulcer Activity.pdf
- 6.4.4.4.0.0.6.2009.The gastric HK-ATPase. structure, function, and inhibition.pdf
- 6.4.4.9.0.0.2.2005.Effect of the Carbonic Anhydrase Inhibitor.pdf
- Video
- A Brief Introduction to Refluxing-b6xFAEkjmGg.mkv
- Abacavir_3VRI_441300_Low.webm
- Acyclovir_2KI5_2022_Low.webm
- Amprenavir_3EKV_65016_Low.webm
- Atazanavir_3EKY_148192_Low.webm
- Boceprevir_3LOX_10324367_Low.webm
- BoehringerIngelheim.Development_of_a_Medicine.wmv
- Brivudine_1OSN_446727_Low.webm
- CCR5_Maraviroc_4MBS_3002977_Low.webm
- CMV_Polymerase_Foscarnet_3KD1_3415_Low.webm
- Darunavir_4LL3_213039_Low.webm
- Delavirdine_1KLM_5625_Low.webm
- Development_of_a_Medicine.mkv
- Didanosine_1V3Q_50599_Low.webm
- Dolutegravir_3S3M_54726191_Low.webm
- Efavirenz_1JKH_64139_Low.webm
- Elvitegravir_3L2U_5277135_Low.webm
- Emtricitabine_2NO6_60877_Low.webm
- Enfuvirtide_2X7R_16130199_Low.m4v
- Entecavir_153941_Low.webm
- Etravirine_3MEC_193962_Low.webm
- FDA.WhatAreClinicalTrialPhases.mkv
- FDA.WhatAreClinicalTrialPhases.wmv
- Foscarnet_3KD1_3415_Low.webm
- Ganciclovir_1KI2_3454_Low.webm
- HCVNS5B_Sofosbuvir_4WTG_45375808_Low.webm
- HCVProtease_Simeprevir_3KEE_24873435_Low.webm
- HIVProtease_Lopinavir_2Q5K_92727_Low.webm
- HIVRT_Nevirapine_4PUO_4463_Low.webm
- HIVRT_Tenofovir_1T03_6398764_Low.webm
- Idoxuridine_1KI7_5905_Low.webm
- Indinavir_3WSJ_5362440_Low.webm
- InfluenzaA_Matrix2_Amantadine_2KAD_2130_Low.webm
- InfluenzaA_Neuraminidase_Laninamivir_3TIB_9847629_Low.webm
- InfluenzaA_Neuraminidase_Zanamivir_2HTQ_60855_Low.webm
- KillerConeSnailsNationalGeographic.mp4
- KillerConeSnailsNationalGeographic.wmv
- Lamivudine_2NOA_60825_Low.webm
- Lopinavir_2Q5K_92727_Low.webm
- Maraviroc_4MBS_3002977_Low.webm
- Nelfinavir_3EKX_64143_Low.webm
- Nevirapine_4PUO_4463_Low.webm
- Oseltamivir_3CL2_65028_Low.webm
- PassiveTransportSpecialTypesOfDiffusion-AnimatedMembranePhysiology.mkv
- Penciclovir_1KI3_4725_Low.webm
- Raltegravir_3L2V_54671008_Low.webm
- Ribavirin_3SFU_37542_Low.webm
- Rilpivirine_3MEE_6451164_Low.webm
- Rimantadine_2RLF_5071_Low.webm
- Ritonavir_1HXW_392622_Low.webm
- Saquinavir_3EKQ_441243_Low.m4v
- Stavudine_18283_Low.webm
- Telaprevir_3SV6_3010818_Low.webm
- ThymidineKinase_Acyclovir_2KI5_2022_Low.webm
- ThymidineKinase_Brivudine_1OSN_446727_Low.webm
- ThymidineKinase_Idoxuridine_1KI7_5905_Low.webm
- Tipranavir_2O4P_54682461_Low.webm
- Valaciclovir_4AQL_60773_Low.webm
- Vidarabine_1PW7_21704_Low.webm
- yt5s.com-Microtubule inhibitors ~pharmacology~(720p).mp4
- yt5s.com-Paclitaxel_ Mechanism of action.mp4
- yt5s.com-Safety and efficacy of an HIV-1 attachment inhibitor(720p).mp4
- Zalcitabine_24066_Low.webm
- Zanamivir_2HTQ_60855_Low.webm
- Zidovudine_3KLF_35370_Low.webm